Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

This trial is testing senaparib (a PARP inhibitor that blocks DNA repair in cancer cells) combined with temozolomide (a chemotherapy drug) in women with a specific type of recurrent ovarian, fallopian tube, or peritoneal cancer that carries a mutation in the ARID1A gene. This combination is designed to exploit a weakness in cancer cells with that mutation. **You may be eligible if...** - Your cancer has been confirmed as recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal carcinoma - Your tumor shows an ARID1A mutation confirmed by genetic sequencing (NGS) - At least 50% of your tumor is clear cell or endometrioid in type (confirmed by pathology) - You are in good enough health to participate - You are willing to use contraception if you could become pregnant **You may NOT be eligible if...** - Your ARID1A mutation has not been confirmed - You have certain blood count or organ function abnormalities - You have active autoimmune disease or other conditions that would interfere Talk to your doctor to see if this trial is right for you.